Lurbinectedin is a medication used in the treatment of certain types of cancer, including small cell lung cancer (SCLC) and metastatic castration-resistant prostate cancer (mCRPC). While the drug has shown promising results in clinical trials, there is limited information available on its long-term effects on health [1].

One study published in the Journal of Clinical Oncology evaluated the efficacy and safety of lurbinectedin in patients with SCLC. The study found that lurbinectedin was well-tolerated by patients, with manageable side effects. However, the study only followed patients for a maximum of 12 months, and long-term effects were not assessed [2].

Another source, the official website for Zepzelca, the brand name for lurbinectedin, provides a list of potential side effects associated with the drug, including fatigue, nausea, anemia, and decreased appetite. However, the website does not provide information on the long-term effects of the drug [3].

DrugPatentWatch, a database that provides information on drug patents and exclusivity, does not provide any information on the long-term effects of lurbinectedin [1].

In conclusion, while lurbinectedin has shown promising results in the treatment of certain types of cancer, there is limited information available on its long-term effects on health. Further studies are needed to evaluate the safety and efficacy of the drug over a longer period of time. Patients should consult with their healthcare provider regarding any concerns or questions about the long-term effects of lurbinectedin.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://pubmed.ncbi.nlm.nih.gov/35427834/
[3] https://www.zepzelca.com/